FDA Eases Clozapine REMS Recs; Auvelity Hits Shelves; Mass Murderers & Psychosis

— News and commentary from the psychiatry world

MedicalToday
Illustration of a brain shaped maze.

In order to make sure there's no disruption in , the FDA said it's "temporarily exercising additional enforcement discretion" in regards to certain REMS program requirements.

Listening to , especially while outside, significantly improved people's mental wellbeing even among those with major depressive disorder. (Scientific Reports)

Women who started prior to the age of 50 saw a twofold higher risk for depression the year immediately after starting. This was seen among women taking estrogen alone or estrogen combined with progestin. (JAMA Network Open)

880: that's the number of patients who were on Massachusetts General Hospital's over the summer. (Washington Post)

Following its FDA approval in August, the oral NMDA receptor antagonist is officially available for prescription, said maker Axsome Therapeutics.

A majority of the perpetrators that at least in part took place at an academic setting did not have severe mental illness, according to an analysis of the Columbia Mass Murder Database. (Journal of Forensic Sciences)

Despite the fact that half of people who died by suicide in 2020 used a firearm, said they felt that restricting access wouldn't prevent suicide. (JAMA Network Open)

From 2017 to 2021, the prevalence rate of in Black children nearly doubled, from 2.05% to 4.01%. (JAMA Network Open)

  • author['full_name']

    Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.